Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
COMPLEMENT-INHIBITORY HYBRID PROTEIN MUTANT AND ANTIBODY FUSION PROTEIN THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/099320
Kind Code:
A1
Abstract:
A hybrid protein containing a CFH functional unit and a DAF functional unit, and a mutant thereof, an encoding nucleic acid thereof, and a method and the use thereof for treating diseases or conditions related to a complement system; and a fusion protein constructed on the basis of the hybrid protein mutant and an antibody specifically binding to complement C5. Further provided are a polynucleotide for encoding said fusion protein, an expression vector and a host cell, a pharmaceutical composition thereof, and a method and the use thereof for treating C5-protein-related diseases.

Inventors:
MA HAILI (CN)
LIU HENG (CN)
Application Number:
PCT/CN2023/130258
Publication Date:
May 16, 2024
Filing Date:
November 07, 2023
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
LONGBIO PHARMA SUZHOU CO LTD (CN)
International Classes:
C07K19/00; A61K38/17; A61P7/04; A61P43/00; C12N5/10; C12N15/62; C12N15/85
Attorney, Agent or Firm:
ZHONGZI LAW OFFICE (CN)
Download PDF: